News | March 16, 2026
GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The data highlights its RSV vaccine cuts hospitalizations in older adults
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Decision on EU marketing authorisation for this population expected by September 2024
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Subscribe To Our Newsletter & Stay Updated
